Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kevin R Flaherty

Showing results (111-120 of 204) with videos related to

Pageof 21
Sort By:
Annals of the American Thoracic Society|September 11, 2023
Deep Learning-based Fibrosis Extent on Computed Tomography Predicts Outcome of Fibrosing Interstitial Lung Disease Independent of Visually Assessed Computed Tomography PatternAndrea S Oh, David A Lynch, Jeffrey J Swigris, et al.
American Journal of Respiratory and Critical Care Medicine|October 22, 2016
Idiopathic Pulmonary Fibrosis: The Association between the Adaptive Multiple Features Method and Fibrosis OutcomesMargaret L Salisbury, David A Lynch, Edwin J R van Beek, et al.
BMC Pulmonary Medicine|July 16, 2020
Expert consensus on the management of adverse events and prescribing practices associated with the treatment of patients taking pirfenidone for idiopathic pulmonary fibrosis: a Delphi consensus studyFranck F Rahaghi, Zeenat Safdar, Anne Whitney Brown, et al.
American Journal of Respiratory and Critical Care Medicine|January 9, 2010
Clinical predictors of a diagnosis of idiopathic pulmonary fibrosisCharlene D Fell, Fernando J Martinez, Lyrica X Liu, et al.
American Journal of Respiratory and Critical Care Medicine|April 30, 2019
Patient Registries in Idiopathic Pulmonary FibrosisDaniel A Culver, Jürgen Behr, John A Belperio, et al.
BMJ Open Respiratory Research|March 10, 2026
Bexotegrast for treatment of idiopathic pulmonary fibrosis (BEACON-IPF): study protocol for a multinational, phase 2b/3, double-blind, randomised, multicentre, controlled trialWim A Wuyts, Lisa Lancaster, Toby M Maher, et al.
Scientific Reports|July 1, 2017
Erratum: The peripheral blood proteome signature of idiopathic pulmonary fibrosis is distinct from normal and is associated with novel immunological processesDavid N O'Dwyer, Katy C Norman, Meng Xia, et al.
The European Respiratory Journal|July 2, 2021
Effects of nintedanib by inclusion criteria for progression of interstitial lung diseaseToby M Maher, Kevin K Brown, Michael Kreuter, et al.
BMJ Open Respiratory Research|October 12, 2017
Design of the PF-ILD trial: a double-blind, randomised, placebo-controlled phase III trial of nintedanib in patients with progressive fibrosing interstitial lung diseaseKevin R Flaherty, Kevin K Brown, Athol U Wells, et al.
Respirology (Carlton, Vic.)|February 28, 2022
Predictors of mortality in subjects with progressive fibrosing interstitial lung diseasesKevin K Brown, Yoshikazu Inoue, Kevin R Flaherty, et al.
Pageof 21

Showing results (111-120 of 204) with videos related to

Sort By:
Pageof 21
Annals of the American Thoracic Society|September 11, 2023
Deep Learning-based Fibrosis Extent on Computed Tomography Predicts Outcome of Fibrosing Interstitial Lung Disease Independent of Visually Assessed Computed Tomography PatternAndrea S Oh, David A Lynch, Jeffrey J Swigris, et al.
American Journal of Respiratory and Critical Care Medicine|October 22, 2016
Idiopathic Pulmonary Fibrosis: The Association between the Adaptive Multiple Features Method and Fibrosis OutcomesMargaret L Salisbury, David A Lynch, Edwin J R van Beek, et al.
BMC Pulmonary Medicine|July 16, 2020
Expert consensus on the management of adverse events and prescribing practices associated with the treatment of patients taking pirfenidone for idiopathic pulmonary fibrosis: a Delphi consensus studyFranck F Rahaghi, Zeenat Safdar, Anne Whitney Brown, et al.
American Journal of Respiratory and Critical Care Medicine|January 9, 2010
Clinical predictors of a diagnosis of idiopathic pulmonary fibrosisCharlene D Fell, Fernando J Martinez, Lyrica X Liu, et al.
American Journal of Respiratory and Critical Care Medicine|April 30, 2019
Patient Registries in Idiopathic Pulmonary FibrosisDaniel A Culver, Jürgen Behr, John A Belperio, et al.
BMJ Open Respiratory Research|March 10, 2026
Bexotegrast for treatment of idiopathic pulmonary fibrosis (BEACON-IPF): study protocol for a multinational, phase 2b/3, double-blind, randomised, multicentre, controlled trialWim A Wuyts, Lisa Lancaster, Toby M Maher, et al.
Scientific Reports|July 1, 2017
Erratum: The peripheral blood proteome signature of idiopathic pulmonary fibrosis is distinct from normal and is associated with novel immunological processesDavid N O'Dwyer, Katy C Norman, Meng Xia, et al.
The European Respiratory Journal|July 2, 2021
Effects of nintedanib by inclusion criteria for progression of interstitial lung diseaseToby M Maher, Kevin K Brown, Michael Kreuter, et al.
BMJ Open Respiratory Research|October 12, 2017
Design of the PF-ILD trial: a double-blind, randomised, placebo-controlled phase III trial of nintedanib in patients with progressive fibrosing interstitial lung diseaseKevin R Flaherty, Kevin K Brown, Athol U Wells, et al.
Respirology (Carlton, Vic.)|February 28, 2022
Predictors of mortality in subjects with progressive fibrosing interstitial lung diseasesKevin K Brown, Yoshikazu Inoue, Kevin R Flaherty, et al.
Pageof 21